C. Boz And M. F. Yetkin, "Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up," ECTRIMS 2019 – 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis , vol.25, no.2, Stockholm, Sweden, pp.806-889, 2019
Boz, C. And Yetkin, M. F. 2019. Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up. ECTRIMS 2019 – 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis , (Stockholm, Sweden), 806-889.
Boz, C., & Yetkin, M. F., (2019). Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up . ECTRIMS 2019 – 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (pp.806-889). Stockholm, Sweden
Boz, Cavit, And MEHMET FATİH YETKİN. "Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up," ECTRIMS 2019 – 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, Sweden, 2019
Boz, Cavit And Yetkin, MEHMET F. . "Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up." ECTRIMS 2019 – 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis , Stockholm, Sweden, pp.806-889, 2019
Boz, C. And Yetkin, M. F. (2019) . "Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up." ECTRIMS 2019 – 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis , Stockholm, Sweden, pp.806-889.
@conferencepaper{conferencepaper, author={Cavit Boz And author={MEHMET FATİH YETKİN}, title={Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up}, congress name={ECTRIMS 2019 – 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis}, city={Stockholm}, country={Sweden}, year={2019}, pages={806-889} }